The use of deep learning models to predict progression-free survival in patients with neuroendocrine tumors

被引:2
|
作者
Pavel, Marianne [1 ]
Dromain, Clarisse [2 ]
Ronot, Maxime [3 ]
Schaefer, Niklaus [2 ]
Mandair, Dalvinder [4 ]
Gueguen, Delphine [5 ]
Elvira, David [5 ]
Jegou, Simon [6 ]
Balazard, Felix [6 ]
Dehaene, Olivier [6 ]
Schutte, Kathryn [6 ]
机构
[1] Friedrich Alexander Univ Erlangen Nurnberg, Dept Med 1, Erlangen, Germany
[2] Lausanne Univ Hosp, Lausanne, Switzerland
[3] Beaujon Hosp, Clichy, France
[4] Royal Free Hosp, London, England
[5] Ipsen, Boulogne Billancourt, France
[6] Owkin, Paris, France
关键词
artificial intelligence; deep learning; neuroendocrine tumors; progression-free survival; RECIST; CONSENSUS GUIDELINES; CLINICAL UTILITY; CHROMOGRANIN-A; DIAGNOSIS; METASTASES; MANAGEMENT; RADIOMICS; RECIST;
D O I
10.2217/fon-2022-1136
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Plain language summary - The use of deep learning models to predict progression-free survival in patients with neuroendocrine tumorsNeuroendocrine tumors (NET) are slow-growing cancers. How well cancers respond to treatment is usually measured using 'Response Evaluation Criteria in Solid Tumors (RECIST)', which is based on measuring the size of tumors. RECIST is not well suited for assessing NETs as these tumors often grow slowly and rarely shrink significantly, so it is difficult to tell whether a treatment has any effect. A better way of measuring how well NETs are responding to treatment is needed, to ensure that patients receive the right treatment as early as possible.The RAISE project aimed to use a type of artificial intelligence (AI) called 'deep learning' to examine images of NETs, taken from patients in a clinical trial of treatment with lanreotide, to help predict how they might respond to treatment. These images were analyzed by the deep learning AI to see if there are any features of tumors, other than shape or size, that may help to predict response to treatment.The project showed that this technology can detect features in images of NETs, other than the shape and size of tumors, that are useful for predicting how well a treatment might work for an individual patient. However, this technology could not improve prediction of how well a treatment would work at an earlier stage compared with other currently used indicators.Overall, further research and work is needed to improve this technology. However, these results show that deep learning may have the potential to improve prediction of treatment response in patients with NETs. Aim: The RAISE project assessed whether deep learning could improve early progression-free survival (PFS) prediction in patients with neuroendocrine tumors. Patients & methods: Deep learning models extracted features from CT scans from patients in CLARINET (NCT00353496) (n = 138/204). A Cox model assessed PFS prediction when combining deep learning with the sum of longest diameter ratio (SLDr) and logarithmically transformed CgA concentration (logCgA), versus SLDr and logCgA alone. Results: Deep learning models extracted features other than lesion shape to predict PFS at week 72. No increase in performance was achieved with deep learning versus SLDr and logCgA models alone. Conclusion: Deep learning models extracted relevant features to predict PFS, but did not improve early prediction based on SLDr and logCgA.
引用
收藏
页码:2185 / 2199
页数:15
相关论文
共 50 条
  • [11] Progression-free survival as a surrogate endpoint in advanced neuroendocrine neoplasms
    Imaoka, Hiroshi
    Sasaki, Mitsuhito
    Takahashi, Hideaki
    Hashimoto, Yusuke
    Ohno, Izumi
    Mitsunaga, Shuichi
    Watanabe, Kazuo
    Umemoto, Kumiko
    Kimura, Gen
    Suzuki, Yuko
    Ikeda, Masafumi
    ENDOCRINE-RELATED CANCER, 2017, 24 (09) : 475 - 483
  • [12] A machine learning approach applied to gynecological ultrasound to predict progression-free survival in ovarian cancer patients
    Francesca Arezzo
    Gennaro Cormio
    Daniele La Forgia
    Carla Mariaflavia Santarsiero
    Michele Mongelli
    Claudio Lombardi
    Gerardo Cazzato
    Ettore Cicinelli
    Vera Loizzi
    Archives of Gynecology and Obstetrics, 2022, 306 : 2143 - 2154
  • [13] An MRI-based radiomics nomogram to predict progression-free survival in patients with endometrial cancer
    Liu, Ling
    Ji, Xiaodong
    Liang, Caihong
    Zhu, Jinxia
    Huang, Lixiang
    Zhao, Yujiao
    Xu, Xiangfeng
    Song, Zhiyi
    Shen, Wen
    FUTURE ONCOLOGY, 2024,
  • [14] Ki-67 proliferative index predicts progression-free survival of patients with well-differentiated ileal neuroendocrine tumors
    Dhall, Deepti
    Mertens, Richard
    Bresee, Catherine
    Parakh, Rugvedita
    Wang, Hanlin L.
    Li, Marissa
    Dhall, Girish
    Colquhoun, Steven D.
    Ines, Delma
    Chung, Fai
    Yu, Run
    Nissen, Nicholas N.
    Wolin, Edward
    HUMAN PATHOLOGY, 2012, 43 (04) : 489 - 495
  • [15] 64Cu-DOTATATE PET/CT and Prediction of Overall and Progression-Free Survival in Patients with Neuroendocrine Neoplasms
    Carlsen, Esben Andreas
    Johnbeck, Camilla Bardram
    Binderup, Tina
    Loft, Mathias
    Pfeifer, Andreas
    Mortensen, Jann
    Oturai, Peter
    Loft, Annika
    Berthelsen, Anne Kiil
    Langer, Seppo W.
    Knigge, Ulrich
    Kjaer, Andreas
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (10) : 1491 - 1497
  • [16] Estimating Progression-Free Survival in Patients with Primary High-Grade Glioma Using Machine Learning
    Kwiatkowska-Miernik, Agnieszka
    Wasilewski, Piotr Gustaw
    Mruk, Bartosz
    Sklinda, Katarzyna
    Bujko, Maciej
    Walecki, Jerzy
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (20)
  • [17] Preoperative Tumor Growth Rate Does Not Predict Overall or Progression-free Survival in Patients With Glioblastoma
    Leppert, Jan
    Ditz, Claudia
    Matschke, Jakob
    Matone, Maria Vittoria
    Kuppler, Patrick
    Hillbricht, Christina
    Krenzlin, Harald
    Keric, Naureen
    Schacht, Hannes
    Ziemann, Christian
    Groh, Elisa Maria
    Liubich, Larysa
    Zemskova, Oksana
    Rades, Dirk
    Loeser, Anastassia
    ANTICANCER RESEARCH, 2024, 44 (11) : 5043 - 5049
  • [18] Overview: Progression-Free Survival as an Endpoint in Clinical Trials with Solid Tumors
    Korn, Ronald L.
    Crowley, John J.
    CLINICAL CANCER RESEARCH, 2013, 19 (10) : 2607 - 2612
  • [19] Development and Validation of Nomograms to Predict the Overall Survival and Progression-Free Survival in Patients with Advanced Unresectable Intrahepatic Cholangiocarcinoma
    Xian, Feng
    Song, Xuewu
    Bie, Jun
    Xu, Guohui
    CANCER MANAGEMENT AND RESEARCH, 2024, 16 : 1835 - 1849
  • [20] 64Cu-DOTATATE PET/CT Predicts Progression-Free Survival in Patients with Neuroendocrine Neoplasms
    Carlsen, E. A.
    Johnbeck, C. B.
    Binderup, T.
    Loft, M.
    Pfeifer, A.
    Mortensen, J.
    Oturai, P.
    Loft, A.
    Berthelsen, A. K.
    Langer, S.
    Knigge, U.
    Kjaer, A.
    NEUROENDOCRINOLOGY, 2020, 110 : 250 - 250